Personalis, Inc. (NASDAQ:PSNL – Get Rating) CFO Aaron Tachibana sold 3,474 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $3.48, for a total value of $12,089.52. Following the completion of the sale, the chief financial officer now owns 223,669 shares of the company’s stock, valued at approximately $778,368.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Personalis Stock Performance
PSNL traded down $0.13 during trading on Thursday, hitting $3.08. The stock had a trading volume of 403,254 shares, compared to its average volume of 522,703. The firm has a market capitalization of $141.43 million, a P/E ratio of -1.47 and a beta of 1.64. The company’s 50-day moving average price is $3.91 and its 200 day moving average price is $5.07. Personalis, Inc. has a twelve month low of $3.00 and a twelve month high of $21.69.
Personalis (NASDAQ:PSNL – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. The company had revenue of $18.24 million for the quarter, compared to analysts’ expectations of $15.06 million. Personalis had a negative net margin of 122.53% and a negative return on equity of 31.55%. As a group, equities analysts expect that Personalis, Inc. will post -2.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Personalis
Analysts Set New Price Targets
Several research analysts have issued reports on the stock. HC Wainwright lowered their price objective on shares of Personalis from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. BTIG Research decreased their price objective on Personalis to $11.00 in a research report on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.50.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.
- Get a free copy of the StockNews.com research report on Personalis (PSNL)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.